Aethlon Medical (AEMD) Emerging Growth Conference summary

Company and technology overview

• Developing Hemopurifier, a blood filtration device targeting harmful substances like extracellular vesicles (EVs) and viruses.

• Device uses plant lectin GNA and diatomaceous earth to filter plasma, aiming to reduce cancer progression and immune suppression.

• Lead clinical focus is oncology, with additional exploration in long COVID and other diseases where EVs are implicated.

• Device is compatible with standard hospital blood pumping machines, including dialysis and CRRT.

• Broader platform potential is being explored internally and with academic partners.

Clinical trial progress and findings

• Australian Oncology Study is in its final cohort, testing three treatments per patient over one week.

• Cohort 2 showed more consistent and longer-lasting decreases in EVs and microRNAs linked to cancer, with increases in lymphocyte subsets.

• Multiple treatments appear to extend the duration and magnitude of EV reduction, supporting the hypothesis of mechanical removal.

• No device-related serious adverse events reported after approximately 150 treatments, indicating a strong safety profile.

• Final cohort data will inform the design of a structured efficacy study and regulatory discussions.

Forward-looking statements and milestones

• Key milestones include completing the final cohort, analyzing the full data set, and engaging with regulatory authorities.

• Next steps may involve a more structured efficacy study if current trends are confirmed.

• Broader platform development continues, with ongoing research in long COVID and other EV-related diseases.

• Advancing new indications will require additional capital, partnerships, or grants.

• Cash resources of approximately $8.9 million are expected to fund operations for at least the next 12 months.